Efficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-Analysis

Abstract Background Upper Facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment, yet comprehensive synthesized evidence is limited. Objectives To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP and ClinicalTrials.gov were performed to identify RCTs evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs) and headaches. Results Three RCTs (n=704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared to placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89–46.73), HFLs (RR 19.17, 95% CI: 9.23–39.80), and LCLs (RR 11.68, 95% CI: 7.49–18.20), all p<0.00001. A ≥2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all p<0.00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11–2.46, p<0.00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, p=0.03). There was no significant difference in TEAEs and headaches from placebo. Conclusions IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile versus placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation.

Authors

Institutions

Publication Details

Journal
Aesthetic Surgery Journal Open Forum
Published
2026-05-08
DOI
https://doi.org/10.1093/asjof/ojag085
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-Analysis

Dr Muhammad Tayyab Azam, Muhammad Hussain Azam, Muhammad Hassan Azam, Muhammad Arif Khan et al.
Aesthetic Surgery Journal Open Forum
Botulinum Toxin and Related Neurological Disorders
article

Efficacy and Safety of IncobotulinumtoxinA for the Simultaneous Treatment of Upper Facial Lines: A GRADE Assessed Systematic Review and Meta-Analysis

Dr Muhammad Tayyab Azam, Muhammad Hussain Azam, Muhammad Hassan Azam, Muhammad Arif Khan, Shahzad Ashraf, Hasibullah Aminpoor
article en

Abstract

Abstract Background Upper Facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment, yet comprehensive synthesized evidence is limited. Objectives To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP and ClinicalTrials.gov were performed to identify RCTs evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs) and headaches. Results Three RCTs (n=704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared to placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89–46.73), HFLs (RR 19.17, 95% CI: 9.23–39.80), and LCLs (RR 11.68, 95% CI: 7.49–18.20), all p<0.00001. A ≥2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all p<0.00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11–2.46, p<0.00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, p=0.03). There was no significant difference in TEAEs and headaches from placebo. Conclusions IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile versus placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation.

Aesthetic Surgery Journal Open Forum
Kabul University (AF), Dow University of Health Sciences (PK)
Openalex Percentile: Top 6%
Botulinum Toxin and Related Neurological Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.